Search Results - "Nelson, Michael L."

Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection by Kim, Jerome H, Excler, Jean-Louis, Michael, Nelson L

“…RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1 acquisition. The prespecified analysis of immune correlates of risk showed…”
Get full text

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial by Modjarrad, Kayvon, Roberts, Christine C, Mills, Kristin T, Castellano, Amy R, Paolino, Kristopher, Muthumani, Kar, Reuschel, Emma L, Robb, Merlin L, Racine, Trina, Oh, Myoung-don, Lamarre, Claude, Zaidi, Faraz I, Boyer, Jean, Kudchodkar, Sagar B, Jeong, Moonsup, Darden, Janice M, Park, Young K, Scott, Paul T, Remigio, Celine, Parikh, Ajay P, Wise, Megan C, Patel, Ami, Duperret, Elizabeth K, Kim, Kevin Y, Choi, Hyeree, White, Scott, Bagarazzi, Mark, May, Jeanine M, Kane, Deborah, Lee, Hyojin, Kobinger, Gary, Michael, Nelson L, Weiner, David B, Thomas, Stephen J, Maslow, Joel N

“…Middle East respiratory syndrome (MERS) coronavirus causes a highly fatal lower-respiratory tract infection. There are as yet no licensed MERS vaccines or…”
Get full text

Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection by Sereti, Irini, Krebs, Shelly J., Phanuphak, Nittaya, Fletcher, James L., Slike, Bonnie, Pinyakorn, Suteeraporn, O'Connell, Robert J., Rupert, Adam, Chomont, Nicolas, Valcour, Victor, Kim, Jerome H., Robb, Merlin L., Michael, Nelson L., Douek, Daniel C., Ananworanich, Jintanat, Utay, Netanya S.

“…Background. Serious non-AIDS events cause substantial disease and death despite human immunodeficiency virus (HIV) suppression with antiretroviral therapy…”
Get full text

Vaccine protection against Zika virus from Brazil by Larocca, Rafael A., Abbink, Peter, Peron, Jean Pierre S., de A. Zanotto, Paolo M., Iampietro, M. Justin, Badamchi-Zadeh, Alexander, Boyd, Michael, Ng’ang’a, David, Kirilova, Marinela, Nityanandam, Ramya, Mercado, Noe B., Li, Zhenfeng, Moseley, Edward T., Bricault, Christine A., Borducchi, Erica N., Giglio, Patricia B., Jetton, David, Neubauer, George, Nkolola, Joseph P., Maxfield, Lori F., De La Barrera, Rafael A., Jarman, Richard G., Eckels, Kenneth H., Michael, Nelson L., Thomas, Stephen J., Barouch, Dan H.

“…The authors test several candidate vaccines for Zika virus in mouse models and show that single-shot DNA vaccines and inactivated virus vaccines provide…”
Get full text

Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology by Chung, Amy W., Kumar, Manu P., Arnold, Kelly B., Yu, Wen Han, Schoen, Matthew K., Dunphy, Laura J., Suscovich, Todd J., Frahm, Nicole, Linde, Caitlyn, Mahan, Alison E., Hoffner, Michelle, Streeck, Hendrik, Ackerman, Margaret E., McElrath, M. Juliana, Schuitemaker, Hanneke, Pau, Maria G., Baden, Lindsey R., Kim, Jerome H., Michael, Nelson L., Barouch, Dan H., Lauffenburger, Douglas A., Alter, Galit

“…While antibody titers and neutralization are considered the gold standard for the selection of successful vaccines, these parameters are often inadequate…”
Get full text

Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment by Andrasik, Michele P, Broder, Gail B, Wallace, Stephaun E, Chaturvedi, Richa, Michael, Nelson L, Bock, Sally, Beyrer, Chris, Oseso, Linda, Aina, Jasmin, Lucas, Jonathan, Wilson, David R, Kublin, James G, Mensah, George A

“…Longstanding social and economic inequities elevate health risks and vulnerabilities for Black, Indigenous and People of Color (BIPOC) communities. Engagement…”
Get full text

Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand by Robb, Merlin L, Eller, Leigh A, Kibuuka, Hannah, Rono, Kathleen, Maganga, Lucas, Nitayaphan, Sorachai, Kroon, Eugene, Sawe, Fred K, Sinei, Samuel, Sriplienchan, Somchai, Jagodzinski, Linda L, Malia, Jennifer, Manak, Mark, de Souza, Mark S, Tovanabutra, Sodsai, Sanders-Buell, Eric, Rolland, Morgane, Dorsey-Spitz, Julie, Eller, Michael A, Milazzo, Mark, Li, Qun, Lewandowski, Andrew, Wu, Hao, Swann, Edith, O'Connell, Robert J, Peel, Sheila, Dawson, Peter, Kim, Jerome H, Michael, Nelson L

“…Acute human immunodeficiency virus type 1 (HIV-1) infection is a major contributor to transmission of HIV-1. An understanding of acute HIV-1 infection may be…”
Get full text

Hashes are not suitable to verify fixity of the public archived web by Aturban, Mohamed, Klein, Martin, Van de Sompel, Herbert, Alam, Sawood, Nelson, Michael L, Weigle, Michele C

“…Web archives, such as the Internet Archive, preserve the web and allow access to prior states of web pages. We implicitly trust their versions of archived…”
Get full text

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG by Tomaras, Georgia D., Ferrari, Guido, Shen, Xiaoying, Alam, S. Munir, Liao, Hua-Xin, Pollara, Justin, Bonsignori, Mattia, Moody, M. Anthony, Fong, Youyi, Chen, Xi, Poling, Brigid, Nicholson, Cindo O., Zhang, Ruijun, Lu, Xiaozhi, Parks, Robert, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Gilbert, Peter B., Kim, Jerome H., Michael, Nelson L., Montefiori, David C., Haynes, Barton F.

“…Analysis of correlates of risk of infection in the RV144 HIV-1 vaccine efficacy trial demonstrated that plasma IgG against the HIV-1 envelope (Env) variable…”
Get full text

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines by Chung, Amy W, Ghebremichael, Musie, Robinson, Hannah, Brown, Eric, Choi, Ickwon, Lane, Sophie, Dugast, Anne-Sophie, Schoen, Matthew K, Rolland, Morgane, Suscovich, Todd J, Mahan, Alison E, Liao, Larry, Streeck, Hendrik, Andrews, Charla, Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, de Souza, Mark S, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Francis, Donald, Michael, Nelson L, Kim, Jerome H, Bailey-Kellogg, Chris, Ackerman, Margaret E, Alter, Galit

“…The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in Thailand, resulted in an estimated 31.2% efficacy against HIV infection. By…”
Get more information

Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques by McCracken, Michael K, Gromowski, Gregory D, Friberg, Heather L, Lin, Xiaoxu, Abbink, Peter, De La Barrera, Rafael, Eckles, Kenneth H, Garver, Lindsey S, Boyd, Michael, Jetton, David, Barouch, Dan H, Wise, Matthew C, Lewis, Bridget S, Currier, Jeffrey R, Modjarrad, Kayvon, Milazzo, Mark, Liu, Michelle, Mullins, Anna B, Putnak, J Robert, Michael, Nelson L, Jarman, Richard G, Thomas, Stephen J

“…Studies have demonstrated cross-reactivity of anti-dengue virus (DENV) antibodies in human sera against Zika virus (ZIKV), promoting increased ZIKV infection…”
Get full text

Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation by Schuetz, Alexandra, Deleage, Claire, Sereti, Irini, Rerknimitr, Rungsun, Phanuphak, Nittaya, Phuang-Ngern, Yuwadee, Estes, Jacob D, Sandler, Netanya G, Sukhumvittaya, Suchada, Marovich, Mary, Jongrakthaitae, Surat, Akapirat, Siriwat, Fletscher, James L K, Kroon, Eugene, Dewar, Robin, Trichavaroj, Rapee, Chomchey, Nitiya, Douek, Daniel C, O Connell, Robert J, Ngauy, Viseth, Robb, Merlin L, Phanuphak, Praphan, Michael, Nelson L, Excler, Jean-Louis, Kim, Jerome H, de Souza, Mark S, Ananworanich, Jintanat

“…Mucosal Th17 cells play an important role in maintaining gut epithelium integrity and thus prevent microbial translocation. Chronic HIV infection is…”
Get full text

Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study by Clark, Danielle V, Dr, Kibuuka, Hannah, MD, Millard, Monica, MPH, Wakabi, Salim, MD, Lukwago, Luswa, MPH, Taylor, Alison, BS, Eller, Michael A, PhD, Eller, Leigh Anne, PhD, Michael, Nelson L, MD, Honko, Anna N, PhD, Olinger, Gene G, PhD, Schoepp, Randal J, PhD, Hepburn, Matthew J, MD, Hensley, Lisa E, PhD, Robb, Merlin L, MD

“…Summary Background The limited data available for long-term Ebola virus disease health outcomes suggest that sequelae persist for longer than 1 year after…”
Get full text

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection by Zolla-Pazner, Susan, deCamp, Allan, Gilbert, Peter B, Williams, Constance, Yates, Nicole L, Williams, William T, Howington, Robert, Fong, Youyi, Morris, Daryl E, Soderberg, Kelly A, Irene, Carmela, Reichman, Charles, Pinter, Abraham, Parks, Robert, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Andrews, Charla, O'Connell, Robert J, Yang, Zhi-yong, Nabel, Gary J, Kim, Jerome H, Michael, Nelson L, Montefiori, David C, Liao, Hua-Xin, Haynes, Barton F, Tomaras, Georgia D

“…In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an…”
Get full text

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial by Zolla-Pazner, Susan, deCamp, Allan C, Cardozo, Timothy, Karasavvas, Nicos, Gottardo, Raphael, Williams, Constance, Morris, Daryl E, Tomaras, Georgia, Rao, Mangala, Billings, Erik, Berman, Phillip, Shen, Xiaoying, Andrews, Charla, O'Connell, Robert J, Ngauy, Viseth, Nitayaphan, Sorachai, de Souza, Mark, Korber, Bette, Koup, Richard, Bailer, Robert T, Mascola, John R, Pinter, Abraham, Montefiori, David, Haynes, Barton F, Robb, Merlin L, Rerks-Ngarm, Supachai, Michael, Nelson L, Gilbert, Peter B, Kim, Jerome H

“…The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously…”
Get full text

Circulating HIV-Specific Interleukin-21+CD4+ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions by Schultz, Bruce T., Teigler, Jeffrey E., Pissani, Franco, Oster, Alexander F., Kranias, Gregory, Alter, Galit, Marovich, Mary, Eller, Michael A., Dittmer, Ulf, Robb, Merlin L., Kim, Jerome H., Michael, Nelson L., Bolton, Diane, Streeck, Hendrik

“…A central effort in HIV vaccine development is to generate protective broadly neutralizing antibodies, a process dependent on T follicular helper (Tfh) cells…”
Get full text

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge by Bradley, Todd, Pollara, Justin, Santra, Sampa, Vandergrift, Nathan, Pittala, Srivamshi, Bailey-Kellogg, Chris, Shen, Xiaoying, Parks, Robert, Goodman, Derrick, Eaton, Amanda, Balachandran, Harikrishnan, Mach, Linh V., Saunders, Kevin O., Weiner, Joshua A., Scearce, Richard, Sutherland, Laura L., Phogat, Sanjay, Tartaglia, Jim, Reed, Steven G., Hu, Shiu-Lok, Theis, James F., Pinter, Abraham, Montefiori, David C., Kepler, Thomas B., Peachman, Kristina K., Rao, Mangala, Michael, Nelson L., Suscovich, Todd J., Alter, Galit, Ackerman, Margaret E., Moody, M. Anthony, Liao, Hua-Xin, Tomaras, Georgia, Ferrari, Guido, Korber, Bette T., Haynes, Barton F.

“…The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine…”
Get full text

Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys by Barouch, Dan H., Stephenson, Kathryn E., Borducchi, Erica N., Smith, Kaitlin, Stanley, Kelly, McNally, Anna G., Liu, Jinyan, Abbink, Peter, Maxfield, Lori F., Seaman, Michael S., Dugast, Anne-Sophie, Alter, Galit, Ferguson, Melissa, Li, Wenjun, Earl, Patricia L., Moss, Bernard, Giorgi, Elena E., Szinger, James J., Eller, Leigh Anne, Billings, Erik A., Rao, Mangala, Tovanabutra, Sodsai, Sanders-Buell, Eric, Weijtens, Mo, Pau, Maria G., Schuitemaker, Hanneke, Robb, Merlin L., Kim, Jerome H., Korber, Bette T., Michael, Nelson L.

“…The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine development. HIV-1 mosaic antigens are bioinformatically optimized…”
Get full text

Influence of HLA-C Expression Level on HIV Control by Apps, Richard, Qi, Ying, Carlson, Jonathan M., Chen, Haoyan, Gao, Xiaojiang, Thomas, Rasmi, Yuki, Yuko, Del Prete, Greg Q., Goulder, Philip, Brumme, Zabrina L., Brumme, Chanson J., John, Mina, Mallal, Simon, Nelson, George, Bosch, Ronald, Heckerman, David, Stein, Judy L., Soderberg, Kelly A., Moody, M. Anthony, Denny, Thomas N., Zeng, Xue, Fang, Jingyuan, Moffett, Ashley, Lifson, Jeffrey D., Goedert, James J., Buchbinder, Susan, Kirk, Gregory D., Fellay, Jacques, McLaren, Paul, Deeks, Steven G., Pereyra, Florencia, Walker, Bruce, Michael, Nelson L., Weintrob, Amy, Wolinsky, Steven, Liao, Wilson, Carrington, Mary

“…A variant upstream of human leukocyte antigen C (HLA-C) shows the most significant genome-wide effect on HIV control in European Americans and is also…”
Get full text

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 by Liao, Hua-Xin, Bonsignori, Mattia, Alam, S. Munir, McLellan, Jason S., Tomaras, Georgia D., Moody, M. Anthony, Kozink, Daniel M., Hwang, Kwan-Ki, Chen, Xi, Tsao, Chun-Yen, Liu, Pinghuang, Lu, Xiaozhi, Parks, Robert J., Montefiori, David C., Ferrari, Guido, Pollara, Justin, Rao, Mangala, Peachman, Kristina K., Santra, Sampa, Letvin, Norman L., Karasavvas, Nicos, Yang, Zhi-Yong, Dai, Kaifan, Pancera, Marie, Gorman, Jason, Wiehe, Kevin, Nicely, Nathan I., Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Tartaglia, James, Sinangil, Faruk, Kim, Jerome H., Michael, Nelson L., Kepler, Thomas B., Kwong, Peter D., Mascola, John R., Nabel, Gary J., Pinter, Abraham, Zolla-Pazner, Susan, Haynes, Barton F.

“…The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine demonstrated an estimated efficacy of 31%, which correlated…”
Get full text